Gilead’s end-stage confirmatory trials of bladder cancer drug fail
Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to.
Drugs
Health
Pharma
Drugs
Health
Pharma
Gilead signs six global pacts to make, sell generic HIV preventive drug
Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.
Drugs
Health
Pharma
FDA nod for Gilead to expand hepatitis drug to six years or older patients
HQ Team March 28, 2024: US regulator, the FDA has approved Gilead Sciences, Inc.’s supplemental new drug application for treating chronic hepatitis B.
Drugs
Health
Pharma
Gilead Sciences puts last-stage blood cancer trials on hold after FDA order
HQ Team February 8, 2024: Gilead Sciences, Inc., announced it has discontinued trials on a drug to treat blood cancer after the US.
Drugs
Health
Pharma
FDA probing T cell cancer therapies of Gilead Sciences, Novartis, J & J
HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies.
Drugs
Health
Pharma
NTD incidence fall by 80 million people, WHO chief calls for funds
The number of people affected by neglected tropical diseases (NTDs) has fallen by 80 million between 2020 and 2021, a WHO report stated.